CLN3-Related Disorder
文献摘要
Clinical characteristics The spectrum of CLN3-related disorder comprises three CLN3-related phenotypes. Classic CLN3 disease is characterized by severe loss of vision due to retinal dystrophy typically beginning between ages four and seven years followed shortly thereafter by progressive neurologic findings that include cognitive decline, neurobehavioral/psychiatric problems, epilepsy, and parkinsonism. Life span is generally around 20 to 30 years. Protracted CLN3 disease is characterized by vision loss that largely overlaps with that of classic CLN3 disease. The cerebral manifestations have a milder and more slowly progressive course than those of classic CLN3 disease. Individuals may retain functional independence into their twenties or thirties. Life expectancy is extended, with some individuals living into their fifth or sixth decade. However, progression is inevitable, and supportive care needs increase over time. Isolated CLN3-related retinal degeneration due to retinal dystrophy is characterized by vision loss that first manifests in early adulthood initially as difficulty with dark adaptation followed by decreasing central visual acuity. Most of the few individuals reported to date do not exhibit additional manifestations; however, neurologic findings were described in one individual. Diagnosis/testing The diagnosis of a CLN3-related disorder is established in a proband with suggestive findings and biallelic pathogenic variants in CLN3 identified by molecular genetic testing. Management Treatment of manifestations: For individuals with classic and protracted CLN3 disease, multidisciplinary care by specialists in ophthalmology and low vision services, developmental delay / intellectual disability, mental health specialists, neurology to manage seizures and extrapyramidal manifestations, physical therapy and occupational therapy to support activities of daily living, speech-language pathology to address swallowing and communication issues, and cardiology to manage cardiac conduction abnormalities and autophagic vacuolar myopathy; transitional care or continued management by pediatric team as appropriate; family and social work support. For individuals with isolated CLN3-related retinal degeneration, treatment of refractive errors and monitoring for macular edema; low vision services; family and social work support. Surveillance: For individuals with classic and protracted CLN3 disease, monitor vision and ocular manifestations per treating ophthalmologist; developmental and educational assessment per treating clinician; neurobehavioral and psychiatric evaluation as needed; neurology evaluation per treating neurologist; annual EKG starting at age 12 years; echocardiogram starting at age 20 years with frequency per cardiologist; assess family needs at each visit. Genetic counseling CLN3-related disorder is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for a CLN3 pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the CLN3 pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible.